Okumi Medical announced today that it has closed a $32.5 million funding round to support its catheter-based technology.
Based in Aliso Viejo, California, okami develops multiple technologies for peripheral vascular occlusion. To date, we have developed the LOBO (Lin Braided Occluder) Vascular Occlusion System and the Sendero Microcatheter.
LOBO provides interventional physicians with a single-device, one-time solution for occluding a wide range of arterial targets. It also eliminates the need for multiple embolization devices. The proprietary HDBraid technology creates a highly occlusive pore structure that significantly reduces blood flow and promotes blood vessel closure. This platform allows blood vessels throughout the body to be closed quickly and efficiently, helping treat a variety of conditions.
Sendero enables smooth delivery of interventional devices while providing optimal trackability through tortuous peripheral vessels. Okumi has designed an FDA-cleared system for delivery of LOBO-3 and LOBO-5 devices. The system incorporates a hydrophilic coating, stainless steel braid, and a radiopaque market band. This optimizes traceability and allows precise placement of interventional devices. Meanwhile, the lubricious PTFE inner liner allows interventional devices to be introduced with low friction.
New investor Vensana Capital led the funding. Existing investors also participated, including US Venture Partners, Okani board members, and other industry veterans.
“We are honored to have the support of Vensana and our existing investors to advance and bring these important technologies to patients,” said Rhonda Robb, President and CEO of Okami. . “We also appreciate the support and contributions of our employees and physician partners who are working tirelessly to build us into a market leader in vascular occlusion.”
